 |
The Clinical Trials are led by doctors/investigators in JBCRG.
And the purpose is to establish standard treatment for patients and provide substantial evidence.
We implement international collaboration in some researches/studies.
JBCRG-14: 
"Phase II study of Letrozole combined with Cyclophosphamide and Capecitabine(LCX) for Hormone-Sensitive advanced breast cancer(age over 65) "
JBCRG-11TC: 
"Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy."
JBCRG-11CPA:
"Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy."
JBCRG-15:
"Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients "
SUPREMO Trial:
"A randomised phase III trial assessing the role of chest wall irradiation in women."
JBCRG-13:
"A phase II study of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil + epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer."
JBCRG-12:
"Effect of the genetic polymorphism of drug-metabolizing enzymes on blood concentrations of the drug in endocrine therapy for breast cancer"
SOLE study:
"A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer"
JBCRG-10:
"A randomized phase II comparative study of preoperative chemotherapies including Trastuzumab + Cyclophosphamide + Docetaxel for operable HER2 positive breast cancer"
JBCRG-09:
"A randomized study of Docetaxel + Cyclophosphamide (TC), 5-fluorouracil + Epirubicin + Cyclophosphamide (FEC)-TC and TC-FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer"
JBCRG-C02:
"Observational study to evaluate the usefulness of trastuzumab in recurrent breast cancer patients with prior adjuvant chemotherapy with trastuzumab: Cohort II"
JBCRG-C01:
" Observational study to evaluate the usefulness of trastuzumab as adjuvant therapy in patients with HER2 positive primary breast cancer: Cohort I"
JBCRG08 (ALTTO):
"A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer (BIG 2-06 / N063D / EGF 106708.)"
JBCRG07:
"Phase II study of combination therapy of preoperative Letrozole and low-dose Metronomic Cyclophosphamide for postmenopausal / hormone receptor positive breast cancer"
JBCRG06:
"Phase II study of therapy of preoperative Letrozole in postmenopausal / hormone receptor positive / preoperative chemotherapy refractory primary breast cancer"
JBCRG05:
"Phase II study of Letrozole and Docetaxel as preoperative chemotherapy in postmenopausal/hormone receptor positive / neo-adjuvant anthracycline refractory primary breast cancer"
JBCRG04(CREATE-X):
"Investigation of a capecitabine as a postoperative adjuvant chemotherapy in breast cancer patients who were pathologically confirmed to have residual tumors after preoperative chemotherapy: Phase-III comparative study (Ver. 2.0)"
JBCRG-M02:
"Study of letrozole in postmenopausal patients with breast cancer - exploratory research on expression of hormone receptors and its clinical effect -"
JBCRG-M01:
"Study of combination chemotherapy of CPT-11/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer, Phase I/II"
OOTR-N003:
"A randomized controlled study of Docetaxel (T) vs Docetaxel + Capecitabine (TX) as preoperative chemotherapy in operable breast cancer patients who did not experience the disease progression after the 4-cycle of 5-Fluorouracil + Epirubicin + Cyclophosphamide (FEC)"
1 2
